[1] LAROSÉE P,HORNE A,HINES M,et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J].Blood, 2019, 133(23):2465-2477.
[2] CASTELLI A A, ROSENTHAL D G, IGNACIO R G,et al. Hemophagocytic lymphohistiocytosis secondary to human immunodeficiencv virus-associated histoplasmosis[J].Open Forum Infect Dis, 2015, 2(4):140-143.
[3] LIU P, PAN X, CHEN C, et al. Nivolumab treatment ofrelapsed/refractory Epstein-Barr-virus-associated hemophagocytic lympho-histiocytosis in adults[J].Blood,2020, 135(11):826-833.
[4] XU L. Serious consequences of Epstein-Barr virusinfection:hemophagocytic lymphohistocytosis[J].Int J Lab Hematol, 2022, 16(2):78-80.
[5] 杨智,吴伟刚,欧鹏程,等.成人EBV感染临床特点及发生噬血细胞综合征的预测因素[J/CD].新发传染病电子杂志,2022,7(2):35-40.
[6] 宋梦, 倪芳, 高欣, 等.葡萄球菌败血症相关的噬血细胞性淋巴组织细胞增多症七例临床分析[J].中华血液学杂志, 2017,38(5):437-439.
[7] 噬血细胞综合征中国专家联盟, 中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识[J].中华医学杂志,2018, 98(2):91-95.
[8] HENTER J I, SAMUELSSON-HORNE A, ARICO M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation[J].Blood, 2002, 100(7):2367-2373. 《东南大学学报(医学版)》唯一公共邮箱:bjb@pub.seu.edu.cn |